drugset / Trial / NCT00090012

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

NCT00090012

Phase 4 Completed 340 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purposes of this study are to determine: * The effectiveness of olanzapine as compared to quetiapine in treating and preventing the recurrence of a variety of symptoms of schizophrenia and schizoaffective disorder in patients who are obese or overweight. * The safety of olanzapine as compared to quetiapine.

Timeline

Start
2004-07
Primary completion
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule
Subject Quetiapine Small molecule